TREATMENT OF EXPERIMENTAL VISCERAL LEISHMANIASIS IN A T-CELL-DEFICIENT HOST - RESPONSE TO AMPHOTERICIN-B AND PENTAMIDINE

被引:42
作者
MURRAY, HW [1 ]
HARIPRASHAD, J [1 ]
FICHTL, RE [1 ]
机构
[1] NEW YORK HOSP,DEPT PHARM,NEW YORK,NY 10021
关键词
D O I
10.1128/AAC.37.7.1504
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In experimental visceral leishmaniasis, euthymic but not athymic (nude) BALB/c mice respond to conventional treatment with pentavalent antimony, indicating that the in vivo efficacy of antimony is T cell dependent. This finding correlates with frequent antimony treatment failures for T-cell-deficient patients with visceral leishmaniasis. To determine whether the in vivo efficacies of alternative antileishmanial agents also require T cells, Leishmania donovani-infected euthymic and nude BALB/c mice were treated with pentamidine or amphotericin B. Pentamidine induced leishmanistatic activity in euthymic mice but had little effect in nude mice. In contrast, amphotericin B exerted potent leishmanicidal activities in both euthymic and nude animals. These results suggest that amphotericin B may be of particular use for T-cell-deficient patients with visceral leishmaniasis.
引用
收藏
页码:1504 / 1505
页数:2
相关论文
共 50 条
  • [41] Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis
    Ahmed, Abeer H. A. Mohamed
    Brocchini, Stephen
    Croft, Simon L.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (06) : 695 - 702
  • [42] Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B
    Mehdi Karamian
    Mohammad Hossein Motazedian
    Davood Mehrabani
    Khodakaram Gholami
    [J]. Parasitology Research, 2007, 101 : 1431 - 1434
  • [43] Treatment of visceral leishmaniasis with liposomal amphotericin B in three immunocompromised patients
    Rodríguez-Wilhelmi, P
    Panizo, C
    Ruza, E
    Rocha, E
    [J]. MEDICINA CLINICA, 2001, 116 (01): : 37 - 38
  • [44] Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis, DA
    Velissariou, IM
    Stabouli, S
    Mavrikou, M
    Delis, D
    Liapi, G
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (01) : 26 - 30
  • [45] Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda
    Mueller, Y.
    Nguimfack, A.
    Cavailler, P.
    Couffignal, S.
    Rwakimari, J. B.
    Loutan, L.
    Chappuis, F.
    [J]. ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2008, 102 (01): : 11 - 19
  • [46] A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis
    Chattopadhyay, Amitabha
    Jafurulla, Md
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 416 (1-2) : 7 - 12
  • [47] Leishmania major infection in a patient with visceral leishmaniasis:: treatment with Amphotericin B
    Karamian, Mehdi
    Motazedian, Mohammad Hossein
    Mehrabani, Davood
    Gholami, Khodakaram
    [J]. PARASITOLOGY RESEARCH, 2007, 101 (05) : 1431 - 1434
  • [48] Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms
    Mukherjee, Asok Kumar
    Gupta, Gaurav
    Bhattacharjee, Surajit
    Guha, Subhasis Kamal
    Majumder, Saikat
    Adhikari, Anupam
    Bhattachrya, Parna
    Majumdar, Suchandra Bhattacharyya
    Majumdar, Subrata
    [J]. JOURNAL OF INFECTION, 2010, 61 (02) : 173 - 184
  • [49] LIPOSOMAL AMPHOTERICIN-B FOR LEISHMANIASIS TREATMENT OF AIDS PATIENTS UNRESPONSIVE TO ANTIMONIUM COMPOUNDS
    LAZANAS, MC
    TSEKES, GA
    PAPANDREOU, S
    HARHALAKIS, N
    SCANDALI, A
    NIKIFORAKIS, E
    SAROGLOU, G
    [J]. AIDS, 1993, 7 (07) : 1018 - 1019
  • [50] SUCCESSFUL TREATMENT OF ANTIMONY-RESISTANT CUTANEOUS LEISHMANIASIS WITH LIPOSOMAL AMPHOTERICIN-B
    TORRECISNEROS, J
    PRADA, JL
    VILLANUEVA, JL
    VALVERDE, F
    SANCHEZGUIJO, P
    [J]. CLINICAL INFECTIOUS DISEASES, 1994, 18 (06) : 1024 - 1025